ABSTRACT
Decreased anabolic androgen levels are followed by impaired brain energy support and sensing with loss of neural connectivity during physiological aging, providing a neurobiological basis for hormone supplementation. Here, we investigated whether nandrolone decanoate (ND) administration mediates hypothalamic AMPK activation and glucose metabolism, thus affecting metabolic connectivity in brain areas of adult and aged mice. Metabolic interconnected brain areas of rodents can be detected by positron emission tomography using 18FDG-mPET. Albino CF1 mice at 3 and 18 months of age were separated into 4 groups that received daily subcutaneous injections of either ND (15 mg/kg) or vehicle for 15 days. At the in vivo baseline and on the 14th day, brain 18FDG-microPET scans were performed. Hypothalamic pAMPKT172/AMPK protein levels were assessed, and basal mitochondrial respiratory states were evaluated in synaptosomes. A metabolic connectivity network between brain areas was estimated based on 18FDG uptake. We found that ND increased the pAMPKT172/AMPK ratio in both adult and aged mice but increased 18FDG uptake and mitochondrial basal respiration only in adult mice. Furthermore, ND triggered rearrangement in the metabolic connectivity of adult mice and aged mice compared to age-matched controls. Altogether, our findings suggest that ND promotes hypothalamic AMPK activation, and distinct glucose metabolism and metabolic connectivity rearrangements in the brains of adult and aged mice.
Subject(s)
Anabolic Agents , Nandrolone , AMP-Activated Protein Kinases/metabolism , Anabolic Agents/metabolism , Animals , Brain/diagnostic imaging , Brain/metabolism , Dietary Supplements , Fluorodeoxyglucose F18 , Glucose/metabolism , Mice , Nandrolone/metabolism , Nandrolone/pharmacology , Nandrolone Decanoate , Positron-Emission TomographyABSTRACT
Aging hinders the effectiveness of regenerative medicine strategies targeting the repair of volumetric muscle loss (VML) injury. Anabolic steroids have been shown to improve several factors which contribute to the age-related decline in muscle's regenerative capacity. In this study, the impact of exogenous nandrolone decanoate (ND) administration on the effectiveness of a VML regenerative repair strategy was explored using an aged animal model. Unilateral tibialis anterior VML injuries were repaired in 18-month-aged animal models (male Fischer 344 rat) using decellularized human skeletal muscle scaffolds supplemented with autologous minced muscle. The contralateral limb was left untreated/uninjured. Following repair, ND(+) or a carrier control (ND-) was delivered via weekly injection for a period of 8 weeks. At 8 weeks, muscle isometric torque, gene expression, and tissue structure were assessed. ND(+) treatment did not improve contractile torque recovery following VML repair when compared to carrier only ND(-) injection controls. Peak isometric torque in the ND(+) VML repair group remained significantly below contralateral uninjured control values (4.69 ± 1.18vs. 7.46 ± 1.53 N mm/kg) and was statistically indistinguishable from carrier only ND(-) VML repair controls (4.47 ± 1.18 N mm/kg). Gene expression for key myogenic genes (Pax7, MyoD, MyoG, IGF-1) were not significantly elevated in response to ND injection, suggesting continued age related myogenic impairment even in the presence of ND(+) treatment. ND injection did reduce the histological appearance of fibrosis at the site of VML repair, and increased expression of the collagen III gene, suggesting some positive effects on repair site matrix regulation. Overall, the results presented in this study suggest that a decline in regenerative capacity with aging may present an obstacle to regenerative medicine strategies targeting VML injury and that the delivery of anabolic stimuli via ND administration was unable to overcome this decline.
Subject(s)
Nandrolone , Regeneration , Animals , Dietary Supplements , Disease Models, Animal , Male , Muscle, Skeletal/physiology , Nandrolone/pharmacology , RatsABSTRACT
We hypothesized that supraphysiological administration of the anabolic-androgenic steroids (AAS) like testosterone (TEST) and nandrolone decanoate (NAND) might differentially affect synaptic and extrasynaptic components of mitochondrial bioenergetics, thereby resulting in memory impairment. Oil (VEH), NAND or TEST (15 mg/Kg) were daily administered to male CF-1 albino mice for 19-days. We evaluated in the synaptosomes and extrasynaptic mitochondria, Ca2+ influx/efflux, membrane potential ΔÑ°m, oxidative respiratory states, dehydrogenases activity, H2O2 production, Tau phosphorylation, and spatial memory in the Morris water maze (MWM). In synaptosomes, both AAS increased Ca2+ influx and Na+ dependent efflux. In extrasynaptic mitochondria, NAND increased the Ca2+ influx. NAND prominently impaired ΔÑ°m formation and dissipation in synaptosomal and extrasynaptic mitochondria, while the effect of TEST was less pronounced. TEST increased the Reserve Respiratory Capacity in synaptosomes, and NAND decreased dehydrogenases activity in synaptic and extrasynaptic mitochondria. Also, NAND increased H2O2 production by synaptosomes and extrasynaptic mitochondria. NAND increased pTauSer396 in synaptosomes. Both AAS did not impair memory performance on MWM. We highlight that high doses of NAND cause neurotoxic effects to components of synaptic and extrasynaptic mitochondrial bioenergetics, like calcium influx, membrane potential and H2O2 production. TEST was less neurotoxic to synaptic and extrasynaptic mitochondrial bioenergetics responses.
Subject(s)
Mitochondria/drug effects , Nandrolone/pharmacology , Synapses/drug effects , Testosterone Congeners/pharmacology , Testosterone/pharmacology , Animals , Blotting, Western , Calcium/metabolism , Energy Metabolism/drug effects , Hydrogen Peroxide/metabolism , Male , Maze Learning/drug effects , Membrane Potential, Mitochondrial/drug effects , Mice , Mitochondria/metabolism , Nandrolone/adverse effects , Oxygen Consumption/drug effects , Phosphorylation/drug effects , Spatial Memory/drug effects , Synapses/metabolism , Synaptosomes/drug effects , Synaptosomes/metabolism , Testosterone/adverse effects , Testosterone Congeners/adverse effects , tau Proteins/metabolismABSTRACT
Nandrolone Decanoate (ND) is an Anabolic Androgenic Steroid (AAS) that under abusive regimen can lead to multiple physiological adverse effects. Studies of AAS-mediated cardiovascular (CV) alterations were mostly taken from male subjects, even though women are also susceptible to the effects of AAS and gender-specific differences in susceptibility to vascular diseases exist. Here we investigate ND-induced vascular reactivity alterations in both sedentary and exercised female rats and whether these alterations depend on endothelium-derived factors. We show that chronic exposure of female Wistar rats to ND (20mg/Kg/week for 4weeks) impaired the vascular mesenteric bed (MVB) reactivity to vasodilator (acetylcholine) agonist. The endothelium-dependent Nitric Oxide (NO) component was reduced in ND-treated rats, whereas neither the endothelium-derived hyperpolarizing factor (EDHF) component nor prostanoids were altered in the MVBs. Endothelial dysfunction observed in ND-treated rats was associated with decreased eNOS (Ser1177) and Akt (Ser473) phosphorylation sites and upregulation of iNOS and NADPH oxidase expression. Exercise training by weight lifting in water did not improve the vascular alterations induced by ND treatment. ND treatment also significantly reduced the serum levels of estradiol in females, overriding its CV protective effect. These results help uncover the role of ND modulating endothelial function in the setting of CV disease caused by the abuse of AAS in females. If this translates to humans, young women abusing AAS can potentially lose the cardio protective effect rendered by estrogen and be more susceptible to CV alterations.
Subject(s)
Anabolic Agents/pharmacology , Nandrolone/analogs & derivatives , Physical Conditioning, Animal/physiology , Adiposity/drug effects , Animals , Biological Factors/metabolism , Eating/drug effects , Female , Mesenteric Arteries/drug effects , Models, Biological , NADPH Oxidases/metabolism , Nandrolone/pharmacology , Nandrolone Decanoate , Nitric Oxide/metabolism , Nitric Oxide Synthase Type II/metabolism , Prostaglandins/metabolism , Rats , Rats, Wistar , Vasodilation/drug effects , Weight Gain/drug effectsABSTRACT
Reduced fertility is one of the main long-term consequences of chemotherapy given for lymphoma, leukemia, and other malignancies in young women. We examined with a female rat model whether and how dienogest, a fourth-generation progestin, modulates reduced fertility following exposure to gonadotoxic chemotherapy. Female rats were administered cyclophosphamide with or without GnRH agonist and different concentrations of dienogest for 20 days. Animals were sacrificed on Day 29, and the numbers of follicle at primordial, preantral and antral stage in the ovaries were counted histologically. Rats treated with sterile saline solution (as control), cyclophosphamide, cyclophosphamide plus GnRH agonist, and cyclophosphamide plus dienogest were also mated with male rats to evaluate their fertility and pregnancy outcomes. Cyclophosphamide significantly reduced the number of primordial follicles, whereas dienogest suppressed depletion of primordial follicle pool induced by chemotherapy. Although the rats exposed to cyclophosphamide alone failed to deliver live births, co-treatment with dienogest improved the pregnancy outcomes of treated rats. The protective effect of dienogest on chemotherapy-induced ovarian damage and reduced fertility was comparable to that of GnRH agonist. The present results suggest that the co-administration of dienogest and chemotherapy may be a useful strategy in preserving ovarian function and fertility in premenopausal women facing gonadotoxic chemotherapy.
Subject(s)
Antineoplastic Agents, Alkylating/adverse effects , Cyclophosphamide/adverse effects , Fertility Agents/pharmacology , Infertility, Female/drug therapy , Nandrolone/analogs & derivatives , Animals , Drug Evaluation, Preclinical , Female , Fertility Agents/therapeutic use , Gonadotropin-Releasing Hormone/agonists , Infertility, Female/chemically induced , Male , Nandrolone/pharmacology , Nandrolone/therapeutic use , Ovarian Follicle/drug effects , Ovary/drug effects , Pregnancy , Rats, Sprague-DawleyABSTRACT
Anabolic androgenic steroids (AAS) are synthetic derivatives of testosterone with thrombogenic potential in high doses and long-term administration. Taurine, a widely distributed amino-sulfonic acid, is known for its beneficial effects in hypercoagulable states. In order to assess the impact of chronic administration of high doses of AAS and taurine upon haemostasis process in rats, 40 male Wistar rats were divided into four equal groups: control group (group C) - no treatment; androgen group (group A) - received 10 mg/kg per week of nandrolone decanoate (DECA); taurine (group T) - received oral supplementation of 2% taurine in drinking water; androgen and taurine group (group AT) - concomitant administration of DECA and taurine. After 12 weeks, blood samples were collected and haemostasis parameters were assessed with the thrombelastographic (TEG) analysis system: reaction time, clot kinetics (K, α), final clot strength, coagulation index and the clot lysis (Ly30). Nandrolone significantly decreased reaction time in group A compared with control (P<0.001), whereas taurine significantly increase reaction time (P=0.01), and this effect was maintained in group AT compared with group A (P=0.009). Similar differences between groups have been recorded for the clot kinetics parameters K, α. The final clot strength and coagulation index were significantly increased in group A versus group C (P=0.04, respectively P<0.001), but not in group AT versus group C (P>0.05). There were no differences in clot lysis, as shown by Ly30. Nandrolone produces an accelerated clot development and an increased clot firmness in Wistar rats. Taurine association ensures a protective effect against this hypercoagulable state, partially restoring the altered parameters of the coagulation profile.
Subject(s)
Androgens/pharmacology , Hemostasis/drug effects , Nandrolone/analogs & derivatives , Taurine/pharmacology , Administration, Oral , Animals , Blood Coagulation Tests , Male , Nandrolone/antagonists & inhibitors , Nandrolone/pharmacology , Nandrolone Decanoate , Rats , Rats, Wistar , ThrombelastographyABSTRACT
There has recently been constant effort to evaluate therapies that may have a positive effect on bone regeneration. However, there are few studies in the literature on the effects of low-level laser therapy (LLLT) involving tissues treated with anabolic steroids. The present study evaluated the effects of LLLT (AsGaAl 780 nm, 3 J/cm(2), 10 mW, beam spot of 0.04 cm(2), total energy 0.12 J) on the proliferation, adhesion, and differentiation of osteoblasts cultured in the presence of nandrolone decanoate (ND). The MTT method was employed to evaluate cell proliferation and adhesion. Cell differentiation was evaluated by measuring alkaline phosphatase activity. There was a significant decrease in cell proliferation in the irradiated group treated with 50 µM ND when compared to the control group, after 48 h. After 72 h, cell proliferation was significantly greater in the control group than in the irradiated groups treated with the steroid at concentrations of 10, 25, and 50 µM. With regard to cell differentiation, alkaline phosphatase activity was significantly higher in the irradiated group treated with 50 µM ND than in the control group, irradiated non-treated group, and irradiated group treated with 25 µM ND. After 60 min of plating, the irradiated non-treated group and irradiated groups treated with the steroid at concentrations of 5, 10, and 25 µM exhibited a significant increase in cell adhesion compared to the control group. LLLT in combination with a high concentration of steroid inhibited cell proliferation, possibly by inducing cell differentiation, while irradiation combined with lower concentrations of the steroid induced an increase in cell adhesion.
Subject(s)
Cell Adhesion/radiation effects , Low-Level Light Therapy/methods , Nandrolone/analogs & derivatives , Osteoblasts/radiation effects , Alkaline Phosphatase/metabolism , Animals , Cell Adhesion/drug effects , Cell Differentiation/drug effects , Cell Differentiation/radiation effects , Cell Proliferation/drug effects , Cell Proliferation/radiation effects , Cells, Cultured , Nandrolone/pharmacology , Nandrolone Decanoate , Osteoblasts/cytology , Osteoblasts/drug effects , Osteoblasts/metabolism , RatsABSTRACT
7α-methyl-19-nortestosterone (MENT) is an androgen with potent gonadotropin inhibitory activity and prostate-sparing effects. These attributes give MENT advantages over testosterone as a male contraceptive, but, as in the case of testosterone, a partial dose-dependent suppression of spermatogenesis has been observed. Combination of testosterone or MENT with synthetic progestins improves the rate of azoospermia; however, it is unknown whether these combinations affect hormone androgenicity or exert synergistic effects via progestational or androgenic interaction. Herein, using transactivation assays, we examined the ability of MENT alone or combined with several 19-nor-derived synthetic progestins to activate androgen receptor (AR)-dependent gene transcription. In addition, the capability of 7α-methyl-estradiol (7α-methyl-E(2)), an aromatized metabolite of MENT, to transactivate gene transcription via estrogen receptor α (ERα; ESR1) or ERß (ESR2) was also investigated. As expected, MENT induced gene transactivation through either the progesterone receptor (PGR) or the AR. MENT was as efficient as progesterone in activating PGR-mediated reporter gene expression, but it was ten times more potent than testosterone and dihydrotestoterone in activating of AR-driven gene expression. The addition of increasing concentrations of other 19-nortestosterone derivatives (norethisterone or levonorgestrel) did not affect, in a significant manner, the ability of MENT to activate AR-dependent reporter gene transcription. The same results were obtained with different cell lines. 7α-Methyl-E(2) resulted in potent estrogen activity via both ER subtypes with efficiency similar to natural E(2). These results suggest that the addition of 19-nortestosterone-derived progestins, as a hormonal adjuvant in male fertility strategies for effective spermatogenic suppression, does not display any detrimental effect that would interfere with MENT androgenic transcriptional activity.
Subject(s)
Nandrolone/analogs & derivatives , Progestins/pharmacology , Receptors, Androgen/physiology , Transcriptional Activation/drug effects , Cells, Cultured , Contraceptive Agents, Female/administration & dosage , Contraceptive Agents, Female/pharmacology , Drug Combinations , Drug Evaluation, Preclinical , HEK293 Cells , HeLa Cells , Humans , Nandrolone/administration & dosage , Nandrolone/pharmacology , Progestins/administration & dosage , Receptors, Androgen/metabolism , Receptors, Estrogen/agonists , Receptors, Estrogen/metabolism , Receptors, Estrogen/physiology , Receptors, Progesterone/agonists , Receptors, Progesterone/metabolism , Receptors, Progesterone/physiology , Transcription, Genetic/drug effects , Transfection , Treatment OutcomeABSTRACT
OBJECTIVE: To investigate the effect of dienogest on the expression of Toll-like receptor (TLR) 4 in human endometrial epithelial cells. DESIGN: Prospective basic research study. SETTING: Pharmaceutical research center. PATIENT(S): None. INTERVENTION(S): Not applicable. MAIN OUTCOME MEASURE(S): TLR4 in the immortalized progesterone receptor-expressing human endometrial epithelial cell line, EM-PR, was activated with lipopolysaccharide and high-mobility group box 1 (LPS/HMGB1) in the presence or absence of the synthetic progestin dienogest or endogenous progesterone. The production of interleukin (IL)-8, IL-6, and monocyte chemoattractant protein (MCP)-1 and the mRNA expression of TLR4 were measured with the use of ELISA and real-time reverse-transcription polymerase chain reaction respectively and nuclear factor (NF)-κB reporter gene assays were performed. The role of TLR4 was assayed with the use of TLR4-siRNA-transfected cells. RESULT(S): Coadministration of LPS/HMGB1 induced the production of IL-8, IL-6, and MCP-1, TLR4 mRNA expression, and NF-κB activity in EM-PR cells, and dienogest inhibited all of these parameters. TLR4 knockdown using TLR4 siRNA reduced IL-8 production. CONCLUSION(S): Dienogest inhibits TLR4 mRNA expression and subsequent IL-8 production induced by TLR4 agonists via an inhibitory effect on NF-κB activation in human endometrial epithelial cells. This pharmacologic effect of dienogest may contribute to its therapeutic effect on abnormal inflammation of endometrium.
Subject(s)
Endometrium/drug effects , Epithelial Cells/drug effects , HMGB1 Protein/pharmacology , Lipopolysaccharides/pharmacology , Nandrolone/analogs & derivatives , Toll-Like Receptor 4/genetics , Cells, Cultured , Dose-Response Relationship, Drug , Down-Regulation/drug effects , Drug Evaluation, Preclinical , Endometrium/cytology , Endometrium/metabolism , Epithelial Cells/metabolism , Epithelial Cells/physiology , Female , Gene Expression Regulation/drug effects , Gene Knockdown Techniques , Hormone Antagonists/pharmacology , Humans , Interleukin-8/metabolism , Nandrolone/pharmacology , RNA, Small Interfering/pharmacology , Toll-Like Receptor 4/antagonists & inhibitors , Toll-Like Receptor 4/metabolismABSTRACT
In the Syrian hamster (Mesocricetus auratus) glutamate activity has been implicated in the modulation of adolescent anabolic-androgenic steroid (AAS)-induced aggression. The current study investigated the time course of adolescent AAS-induced neurodevelopmental and withdrawal effects on the glutamatergic system and examined whether these changes paralleled those of adolescent AAS-induced aggression. Glutamate activity in brain areas comprising the aggression circuit in hamsters and aggression levels were examined following 1, 2, 3, and 4 weeks of AAS treatment or 1, 2, 3, and 4 weeks following the cessation of AAS exposure. In these studies glutamate activity was examined using vesicular glutamate transporter 2 (VGLUT2). The onset of aggression was observed following 2 weeks exposure to AAS and continued to increase showing maximal aggression levels after 4 weeks of AAS treatment. This aggressive phenotype was detected after 2 weeks of withdrawal from AAS. The time-course of AAS-induced changes in latero-anterior hypothalamus (LAH)-VGLUT2 closely paralleled increases in aggression. Increases in LAH-VGLUT2 were first detected in animals exposed to AAS for 2 weeks and were maintained up to 3 weeks following the cessation of AAS treatment. AAS treatment also produced developmental and long-term alterations in VGLUT2 expression within other aggression areas. However, AAS-induced changes in glutamate activity within these regions did not coincide with changes in aggression. Together, these data indicate that adolescent AAS treatment leads to alterations in the glutamatergic system in brain areas implicated in aggression control, yet only alterations in LAH-glutamate parallel the time course of AAS-induced changes in the aggressive phenotype.
Subject(s)
Aggression/physiology , Anabolic Agents/pharmacology , Androgens/pharmacology , Brain/growth & development , Glutamic Acid/physiology , Substance Withdrawal Syndrome/metabolism , Adolescent , Aggression/drug effects , Anabolic Agents/administration & dosage , Anabolic Agents/adverse effects , Androgens/administration & dosage , Androgens/adverse effects , Animals , Brain/drug effects , Brain/metabolism , Brain/physiology , Cricetinae , Disease Models, Animal , Drug Administration Schedule , Humans , Hypothalamus/drug effects , Hypothalamus/growth & development , Hypothalamus/metabolism , Hypothalamus/physiology , Male , Nandrolone/administration & dosage , Nandrolone/adverse effects , Nandrolone/analogs & derivatives , Nandrolone/pharmacology , Nandrolone Decanoate , Neurons/metabolism , Neurons/physiology , Substance Withdrawal Syndrome/psychology , Testosterone/administration & dosage , Testosterone/adverse effects , Testosterone/analogs & derivatives , Testosterone/pharmacology , Time Factors , Vesicular Glutamate Transport Protein 2/metabolismABSTRACT
Studies have shown that anabolic androgenic steroids (AASs) can induce profound changes to mental health. Commonly reported psychiatric side effects among AAS users include aggression, anxiety, depression, drug abuse and cognitive disabilities. In experimental animals, many of these effects have been associated with alterations in a number of neurotransmitter systems. We have observed that chronic administration of the AAS nandrolone (nandrolone decanoate) can affect excitatory amino acids as well as monoaminergic and peptidergic pathways in a way that is compatible with nandrolone-induced behavioural changes. The aim of the present work was to further explore the mechanisms underlying nandrolone-induced effects, with a particular focus on components known to be involved in aggression and cognitive function. Male rats were given daily injections of nandrolone decanoate for 14 days and the effects on neurosteroid interactions with sites on the N-methyl-D-aspartyl (NMDA) and sigma receptors were examined. These receptors were chosen because of their involvement in aggressive and cognitive behaviors and the hypothesis that nandrolone might affect the brain via interaction with neurosteroids. Radiolabelled [³H]ifenprodil was used in the binding studies because of its significant affinity for the NMDA and sigma receptors. The results indicated that [³H]ifenprodil binds to both sigma-1 and sigma-2 sites and can be displaced to a certain extent from both sites by the neurosteroids pregnenolone sulphate (PS), pregnanolone sulphate (3α5ßS) and dehydroepiandrosterone sulphate (DHEAS). The remainder of the [³H]ifenprodil was displaced from the sigma-1 site by the sigma-1 receptor-selective ligand (+)-SKF 10,047. Chronic nandrolone treatment changed the sigma-1 receptor target for the neurosteroids but not for ifenprodil. The sigma-2 receptor site was unaltered by treatment with nandrolone decanoate. The results also indicated that the neurosteroid-induced allosteric modulation of the NMDA receptor subunit NR2B was not affected by nandrolone treatment. We conclude that chronic treatment with nandrolone changes the affinity of the neurosteroids PS, 3α5ßS and DHEAS at the sigma-1 site but not at the sites on the sigma-2 receptor or the NMDA receptor subunit NR2B.
Subject(s)
Anabolic Agents/pharmacology , Androgens/pharmacology , Frontal Lobe/drug effects , Nandrolone/pharmacology , Neurotransmitter Agents/metabolism , Receptors, sigma/metabolism , Allosteric Regulation/drug effects , Anabolic Agents/administration & dosage , Anabolic Agents/adverse effects , Androgens/administration & dosage , Androgens/adverse effects , Animals , Dehydroepiandrosterone Sulfate/metabolism , Frontal Lobe/metabolism , Kinetics , Male , Nandrolone/administration & dosage , Nandrolone/adverse effects , Nandrolone/analogs & derivatives , Nandrolone Decanoate , Nerve Tissue Proteins/metabolism , Neurons/drug effects , Neurons/metabolism , Pregnanolone/analogs & derivatives , Pregnanolone/metabolism , Pregnenolone/metabolism , Random Allocation , Rats , Rats, Sprague-Dawley , Receptors, N-Methyl-D-Aspartate/metabolism , Sigma-1 ReceptorABSTRACT
Few animal model studies have been conducted in order to evaluate the impact of androgenic anabolic steroids (AAS) supraphysiological doses on the cardiovascular system and myocardial injury. Twenty-five male CD1 mice (8-10 weeks old; 35g initial body weight) were randomized into three AAS treated groups and two control groups. The AAS mice received intramuscular Nandrolone Decanoate (DECA-DURABOLIN), vehicled in arachidis oil, for 42 days, twice per week, with different dosages, studying plasma lipid analysis, cardiac histopathological features, cardiac ß (1) adrenergic receptor expression, and the effects of the myocardial expression of inflammatory mediators (IL-1ß, TNF-α) on the induction of cardiomyocytes apoptosis (HSP 70, TUNEL), using proteomic and immunohistochemical analysis. The mice had free movements in their animal rooms (two groups) or exercised by running on a motor-driven treadmill the others three groups. Recurring high dose AAS administration and physical training in mice produce significant increase in body weight and for total cholesterol. A moderate increase of the heart weight, cardiac hypertrophy and wide colliquative myocytolysis, were observed in high dose AAS administration and physical training group. The expression of HSP70 and inflammatory cytokine IL-1ß, increased in the three AAS-treated groups. TNF- α showed a more extensive expression in the AAS-high dose group. A significant apoptotic process randomly sparse in the myocardium was described. Our data support the hypothesis that the combined effects of vigorous training, anabolic steroid abuse and stimulation of the sympathetic nervous system, may predispose to myocardial injury.
Subject(s)
Anabolic Agents/pharmacology , Cytokines/biosynthesis , Heart/drug effects , Nandrolone/analogs & derivatives , Physical Conditioning, Animal , Receptors, Adrenergic, beta-1/biosynthesis , Tumor Necrosis Factor-alpha/biosynthesis , Anabolic Agents/administration & dosage , Anabolic Agents/toxicity , Animals , Apoptosis/drug effects , Cytokines/metabolism , Heart/physiopathology , In Situ Nick-End Labeling , Lipids/blood , Male , Mice , Models, Animal , Myocardium/metabolism , Nandrolone/administration & dosage , Nandrolone/pharmacology , Nandrolone/toxicity , Nandrolone Decanoate , Random Allocation , Tumor Necrosis Factor-alpha/metabolismABSTRACT
Nandrolone is an anabolic steroid that has been demonstrated to reduce the loss of bone and muscle from hindlimb unweighting and to slow muscle atrophy after nerve transection. To determine whether nandrolone has the ability to protect bone against loss due to disuse after denervation, male rats underwent sciatic nerve transaction, followed 28 days later by treatment with nandrolone or vehicle for 28 days. Bone mineral density (BMD) was determined 28 days later or 56 days after nerve transection. Denervation led to reductions in BMD of 7% and 12% for femur and tibia, respectively. Nandrolone preserved 80% and 60% of BMD in femur and tibia, respectively, demonstrating that nandrolone administration significantly reduced loss of BMD from denervation. This study offers a potential novel pharmacological strategy for use of nandrolone to reduce bone loss in severe disuse- and denervation-related bone loss, such as that which occurs after spinal cord injury.
Subject(s)
Bone Resorption/prevention & control , Denervation , Hindlimb , Nandrolone/therapeutic use , Anabolic Agents/pharmacology , Anabolic Agents/therapeutic use , Animals , Bone Density/drug effects , Bone Resorption/etiology , Disease Models, Animal , Drug Evaluation, Preclinical , Femur/innervation , Femur/pathology , Hindlimb/drug effects , Hindlimb/innervation , Hindlimb/pathology , Male , Nandrolone/pharmacology , Rats , Rats, Wistar , Sciatic Nerve/surgery , Tibia/innervation , Tibia/pathologyABSTRACT
Nandrolone or nortestosterone, an anabolic-androgenic steroid, has been prohibited by doping control regulations for more than 30 years. Although its main metabolism in the human body was already known at that time, and detection of its misuse by gas or liquid chromatographic separation with mass spectrometric detection is straightforward, many interesting aspects regarding this doping agent have appeared since.Over the years, nandrolone preparations have kept their position among the prohibited substances that are most frequently detected in WADA-accredited laboratories. Their forms of application range from injectable fatty acid esters to orally administered nandrolone prohormones. The long detection window for nandrolone ester preparations and the appearance of orally available nandrolone precursors have changed the pattern of misuse.At the same time, more refined analytical methods with lowered detection limits led to new insights into the pharmacology of nandrolone and revelation of its natural production in the body.Possible contamination of nutritional supplements with nandrolone precursors, interference of nandrolone metabolism by other drugs and rarely occurring critical changes during storage of urine samples have to be taken into consideration when interpreting an analytical finding.A set of strict identification criteria, including a threshold limit, is applied to judge correctly an analytical finding of nandrolone metabolites. The possible influence of interfering drugs, urine storage or natural production is taken into account by applying appropriate rules and regulations.
Subject(s)
Anabolic Agents/pharmacology , Doping in Sports , Nandrolone/pharmacology , 5-alpha Reductase Inhibitors , Anabolic Agents/adverse effects , Anabolic Agents/analysis , Anabolic Agents/metabolism , Anabolic Agents/urine , Dietary Supplements , Drug Contamination , Enzyme Inhibitors/pharmacology , Female , Food Contamination , Humans , Male , Menstrual Cycle/physiology , Nandrolone/adverse effects , Nandrolone/analysis , Nandrolone/metabolism , Nandrolone/urine , Pregnancy , Progestins/pharmacologyABSTRACT
The study was undertaken to find out the effects of over supplementation of dietary calcium and vitamin D3 on the mineralization of growing skeleton, taking rabbit as an animal model; further to study the effects of Nandrolone deconoate and TGF-beta1 on the mineralization of osteopenic bones. Twenty four New Zealand White rabbits of either sex, 60 day old, were randomly divided in 4 equal groups, A, B, C and D. The animals of groups B, C and D were administered with oral supplementation of calcium (2000 mg/kg of standard rabbit feed) and vit-D3 (1000 IU/kg of standard feed) for 60 days. The animals of group A were given standard ration without any supplementation. After 60 days, the Ca-vit.D3 supplementation was discontinued; and the animals of group C were administered with TGF-beta1 (10 ng, i.m.) once in every three days and animals of group D were given Nandrolone deconoate (10 mg, i.m.) once every week for 30 days, whereas in animals of group B, no treatment was given. All the animals were evaluated based on different observations like body weight, radiographic observations, circulating biochemical and hormone profile (plasma Ca, IP, AP, OC and iPTH) every 15 days up to 60 days after initiation of treatment. The results indicated that the body weight of rabbits in different groups increased gradually and steadily at different intervals till the end of observation period, however, the increase was non-significantly more in group D. The CI in group A increased gradually at different intervals; whereas in groups B, C and D, there was no appreciable increase in the CI during the period of Ca-vit.D3 supplementation, suggesting development of osteopenia. Treatment with TGF-beta1 did not increase the CI significantly, whereas Nandrolone treatment resulted in significant increase in the CI on days 45 and 60. The plasma Ca levels showed slight but gradual increase from day 0 to 60 in almost all groups. Subsequently also, there was no marked change at different intervals in groups A and B; however, significant reduction in plasma Ca was noticed in group C on 15(th) day and in group D on 60(th) day after initiation of treatment. Plasma IP levels in groups B and C showed a decreasing trend up to day 60. After discontinuation of Ca-vit.D3 supplementation, in group B, it further decreased to remain significantly lower on 15(th) day, and in groups C and D, it increased significantly on 60(th) post-treatment day. There was no significant change in the AP activity during the entire period of study in group A; whereas significant reduction in AP activity was measured on 30(th) and 60(th) days of treatment in groups B and C, and on 15(th) day of treatment in group D. Plasma iPTH values did not show any significant change at any interval during the first 60 days in all groups. On 30(th) and 60(th) days of treatment, the mean iPTH level remained significantly lesser in group B. In all groups treated with over supplementation of Ca and vit.D3, there was a non-significant increase in the plasma OC levels up to day 60; however, there was no significant difference between the groups. It can be concluded that additional supplementation of Ca and vit.D3 results in osteopenia in growing rabbits. Administration of Nandrolone helps to increase the mineral density in osteopenic bones, whereas TGF-beta1 does not seem to have positive effect on the skeletal mineralization.
Subject(s)
Anabolic Agents/pharmacology , Bone Diseases, Metabolic/metabolism , Calcium/administration & dosage , Cholecalciferol/administration & dosage , Nandrolone/analogs & derivatives , Transforming Growth Factor beta1/pharmacology , Alkaline Phosphatase/blood , Animals , Body Weight/drug effects , Body Weight/physiology , Bone Diseases, Metabolic/blood , Bone Diseases, Metabolic/drug therapy , Calcium/blood , Calcium/metabolism , Cholecalciferol/blood , Cholecalciferol/metabolism , Female , Male , Nandrolone/pharmacology , Nandrolone Decanoate , Osteocalcin/blood , Parathyroid Hormone/blood , Phosphorus/blood , Rabbits , Random AllocationABSTRACT
Chronic anabolic-androgenic steroid (AAS) treatment during adolescence facilitates offensive aggression in male Syrian hamsters (Mesocricetus auratus). Serotonin (5-HT) modulates aggressive behavior and has been shown to be altered after chronic treatment with AAS. Furthermore, 5-HT type 2 receptors have been implicated in the control of aggression. For example, treatment with 5-HT(2A) receptor antagonists suppress the generation of the offensive aggressive phenotype. However, it is unclear whether these receptors are sensitive to adolescent AAS exposure. The current study assessed whether treatment with AAS throughout adolescence influenced the immunohistochemical localization of 5-HT(2A) in areas of the hamster brain implicated in the control of aggression. Hamsters were administered AAS (5.0 mg/kg) each day throughout adolescence, scored for offensive aggression, and then examined for differences in 5-HT(2A)-immunoreactivity (5-HT(2A)-ir). When compared with non-aggressive oil-treated controls, aggressive AAS-treated hamsters showed significant increases in 5-HT(2A)-ir fibers in the lateral portion of the anterior hypothalamus (LAH). Further analysis revealed that AAS treatment also produced a significant increase in the number of cells expressing 5-HT(2A)-ir in the LAH. Together, these results support a role for altered 5-HT(2A) expression and further implicate the LAH as a central brain region important in the control of adolescent AAS-induced offensive aggression.
Subject(s)
Aggression/drug effects , Anabolic Agents/pharmacology , Androgens/pharmacology , Hypothalamus/drug effects , Receptor, Serotonin, 5-HT2A/metabolism , Aging , Anabolic Agents/administration & dosage , Androgens/administration & dosage , Animals , Cricetinae , Delayed-Action Preparations , Dihydrotestosterone/administration & dosage , Dihydrotestosterone/pharmacology , Drug Administration Schedule , Hypothalamus/metabolism , Male , Mesocricetus , Nandrolone/administration & dosage , Nandrolone/pharmacology , Receptor, Serotonin, 5-HT2A/drug effects , Testosterone/administration & dosage , Testosterone/analogs & derivatives , Testosterone/pharmacologyABSTRACT
OBJECTIVES: Anabolic-androgenic steroids such as Nandrolone phenpropionate (NP) dramatically improve the tolerance to acute stress conditions, strength, and subsequently the quality of life in elderly men. We hypothesize that preoperative pulse-dose supraphysiological NP administration might improve the early morbid symptoms in older patients undergoing open prostatectomy. METHODS: From 2005 to 2006, 54 patients with a mean age of 70 years, diagnosed as benign prostatic hyperplasia and hospitalized for open prostatectomy were enrolled in the study. They were randomly selected to receive preoperative supraphysiological NP (100 mg, intramuscularly, pulse-dose) or sesame oil placebo, prospectively. Early postoperative morbid symptoms including subjective urinary symptoms (dysuria, bladder retention sensation), incision site pain and general satisfaction of their current urinary condition were assessed by a 6-point scale, self-administrated questionnaire at 24 and 48 h, postoperatively. The sex hormone binding globulin and the testosterone levels were also measured. RESULTS: The 24-h postoperative symptoms were significantly reduced in the NP group compared to the placebo (6.18 +/- 2.81 versus 9.77 +/- 2.15; P < 0.001). The postoperative symptoms were reported to have a decline in the 48 h following operation, though was calculated to be statistically insignificant (4.48 +/- 2.32 versus 5.55 +/- 1.84; P = 0.06). There was no complication attributed to NP therapy. CONCLUSIONS: The data supported the hypothesis that the preoperative anabolic steroid supplements (such as NP) could result in a better postoperative endurance in elderly men undergoing open prostatectomy. Further studies, longer and repeated pulse injections in a larger number of older men are mandatory to prove the claim.
Subject(s)
Anabolic Agents/pharmacology , Androgens/pharmacology , Nandrolone/analogs & derivatives , Postoperative Complications/prevention & control , Preoperative Care , Prostatectomy/methods , Steroids/pharmacology , Aged , Aged, 80 and over , Anabolic Agents/administration & dosage , Humans , Male , Middle Aged , Nandrolone/administration & dosage , Nandrolone/pharmacology , Sesame Oil/administration & dosage , Sesame Oil/pharmacologyABSTRACT
Androgen signaling, mediated by the androgen receptor (AR), is a critical factor influencing growth of normal and malignant breast cells. Given the increasing use of exogenous androgens in women, a better understanding of androgen action in the breast is essential. This study compared the effects of 5alpha-dihydrotestosterone (DHT) and a synthetic androgen, mibolerone, on estradiol (E(2))-induced proliferation of breast cancer cells. DHT modestly inhibited E(2)-induced proliferation and mibolerone significantly inhibited proliferation in T-47D cells. The effects of both androgens could be reversed by an AR antagonist, suggesting that their actions were mediated, in part, by AR. Whereas high physiological doses (10-100nM) of DHT reduced E(2)-mediated induction of the estrogen-regulated gene progesterone receptor (PR) to basal levels, mibolerone at lower doses (1nM) eliminated PR expression, suggesting that mibolerone may also act via the PR. In the AR positive, PR-negative MCF-7 cells, mibolerone had modest effects on E(2)-induced proliferation, but was a potent inhibitor of proliferation in the AR positive, PR positive MCF-7M11 PRA cells. The effects of mibolerone in breast cancer cells were similar to those of the progestin, medroxyprogesterone acetate. Our results demonstrate that mibolerone can have both androgenic and progestagenic actions in breast cancer cells.
Subject(s)
Breast Neoplasms/pathology , Cell Proliferation/drug effects , Nandrolone/analogs & derivatives , Receptors, Androgen/physiology , Receptors, Progesterone/physiology , Androgens , Dihydrotestosterone/pharmacology , Drug Evaluation, Preclinical , Estradiol/pharmacology , Humans , Medroxyprogesterone Acetate/pharmacology , Nandrolone/pharmacology , Progestins/pharmacology , Testosterone Congeners/pharmacology , Tumor Cells, CulturedABSTRACT
OBJECTIVE: To investigate the effect of dienogest on the proliferation of endometriotic stromal cells. DESIGN: Comparative and laboratory study. SETTING: University of Tokyo Hospital. PATIENT(S): Endometriotic stromal cells were isolated and cultured from ovarian endometriomas of patients undergoing surgery. INTERVENTION(S): Dienogest was added to the cultured endometriotic stromal cells. MAIN OUTCOME MEASURE(S): 5-Bromo-2'-deoxyuridine (BrdU) incorporation into DNA of the endometriotic stromal cells was measured by ELISA. Cell cycle analysis of the cultured endometriotic stromal cells was performed by flow cytometry. RESULT(S): Dienogest at concentration of 10(-7) M and 10(-6) M significantly inhibited BrdU incorporation into DNA at 24 and 48 hours. Dienogest significantly increased the cells in G0/G1 phase and reduced the cells in S phase and G2/M phase in 24 and 48 hours. CONCLUSION(S): The present study indicates that dienogest can inhibit the proliferation of the endometriotic stromal cells with G0/G1 arrest, suggesting a possible direct effect of dienogest in the treatment of endometriosis.
Subject(s)
Bromodeoxyuridine/pharmacokinetics , Cell Proliferation/drug effects , Endometriosis/pathology , G1 Phase/drug effects , Nandrolone/analogs & derivatives , Ovarian Diseases/pathology , Resting Phase, Cell Cycle/drug effects , Stromal Cells/pathology , Adult , Cell Cycle/drug effects , Cells, Cultured , Contraceptives, Oral/pharmacology , DNA/metabolism , Drug Evaluation, Preclinical , Endometriosis/metabolism , Female , Humans , Nandrolone/pharmacology , Ovarian Diseases/metabolism , Stromal Cells/metabolismABSTRACT
BACKGROUND & AIMS: Osteoporosis is a major health problem worldwide. Low weight is a major risk factor for low bone mass and fractures. The aim of this study was to investigate the effects on bone tissue of protein-rich supplementation alone or in combination with nandrolone decanoate in lean elderly women after a hip fracture. METHODS: Sixty elderly women with BMI <24 kg/m(2) admitted to hospital due to a femoral neck fracture were randomised to a control group, to receive a protein-rich formula or to receive the same formula with an addition of nandrolone decanoate for 6 months. All patients received additional calcium and vitamin D. The effects after 6 and 12 months were measured by means of bone mineral density (BMD) using dual-energy X-ray absorptiometry (DXA), and with biochemical bone markers. Osteocalcin and C-terminal telopeptide of collagen-1 (CTX) were used to estimate bone formation and bone resorption, respectively. RESULTS: The analyses showed an increase in total body BMD at 6 and 12 months in patients who received protein-rich supplementation. Nandrolone decanoate did not appear to have any additional effect on BMD. Osteocalcin increased in all groups while no significant changes were found for CTX. CONCLUSION: The overall results of the study indicated that protein-rich supplementation given to lean elderly female hip fracture patients increased the total body BMD.